scispace - formally typeset
S

Sarah C. Jernigan

Researcher at University of Louisville

Publications -  12
Citations -  1337

Sarah C. Jernigan is an academic researcher from University of Louisville. The author has contributed to research in topics: Estrogen receptor alpha & Estrogen receptor beta. The author has an hindex of 9, co-authored 10 publications receiving 1259 citations.

Papers
More filters
Journal ArticleDOI

Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta.

TL;DR: It is reported that resveratrol binds ERb and ERa with comparable affinity, but with 7,000-fold lower affinity than estradiol (E2), which indicates that those tissues that uniquely express ERb or that express higher levels of ERb than ERa may be more sensitive to resver atrol’s estrogen agonist activity.
Journal ArticleDOI

Estrogen response element-dependent regulation of transcriptional activation of estrogen receptors α and β by coactivators and corepressors

TL;DR: Testing the hypothesis that alterations in ER conformation induced by binding to different ERE sequences modulates ER interaction with coactivators and corepressors demonstrated that the ERE sequence impacts estradiol-and 4-hydroxytamoxifen-occupied ERalpha and ERbeta interaction with coregulators as measured by transcriptional activity in mammalian cells.
Journal ArticleDOI

Estrogen response element sequence impacts the conformation and transcriptional activity of estrogen receptor alpha.

TL;DR: The results support the hypothesis that the ERE sequence acts as an allosteric effector, altering ER conformation, and speculate that ERE-induced alterations in ERalpha conformation modulate interaction with co-regulatory proteins.
Journal ArticleDOI

Short heterodimer partner (SHP) orphan nuclear receptor inhibits the transcriptional activity of aryl hydrocarbon receptor (AHR)/AHR nuclear translocator (ARNT).

TL;DR: In RL95-2 human endometrial carcinoma cells, SHP inhibited TCDD-stimulated reporter activity from the AHR-responsive CYP1A1 and UGT1A6 gene promoters in a concentration-dependent manner and identified ARNT as a novel SHP target.